RAPIDLY PROGRESSIVE NEPHRITIC SYNDROME IN PATIENTS WITH CRYOGLOBULINEMIC VASCULITIS ASSOCIATED WITH CHRONIC HEPATITIS C

cryoglobulinemic vasculitis, rapidly progressive nephritic syndrome, glomerulonephritis, hepatitis C

1. Ферри К. Смешанная криоглобулинеми. Нефрология 2010; 14 (1)

2. Barry M. Brenner , «Brenner and Rector’s The Kidney» , 8th ed. Saunders 2007, chapter 32

3. D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54: 650–671

4. Perico N, Cattaneo D, Bikbov, B, Remuzzi G. Hepatitis C Infection and Chronic Renal Diseases. Clin J Am Soc Nephrol 2009; 4: 207-220

5. Meyers CM, Seeff LB, Stehman-Breen C O, Hoofnagle JH. Hepatitis C and renal disease: an update, American Journal of Kidney Diseases 2003; 42( 4) 631-657

6. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-623

7. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465–470

8. Garini G, Allegri L, Iannuzzella F, et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapie. Acta Biomed 2007; 78: 51-59

9. Sinico RA, Fornasieri A, D’Amico G. Renal manifestations associated with hepatitis C virus. Ann Med Interne 2000; 151(1): 41-45

10. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Current Opinion in Rheumatology 2008; 20: 23–28

11. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand. Ann Rheum Dis 2008; 67: 283-287

12. Милованова СЮ, Лопаткина ТН, Козловская ЛВ, Краснова ТН. Моноклональные антитела к B-лимфоцитам (ритуксимаб) в лечении HCV-ассоциированного криоглобулинемического гломерулонефрита тяжелого течения. Тер арх 2007; 6: 69-72

13. Forde KA, Reddy KR. Hepatitis C Virus Infection and Immunomodulatory Therapies. Clinics in Liver Disease 2009; 13(3): 391-401

14. Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus–associated glomerulonephritis: current approaches. J Nephrol 2008; 21: 813-825

15. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter Study on Hepatitis C Virus–Related Cryoglobulinemic Glomerulonephritis. Am J Kidney Dis 2007; 49(1): 69-82

16. Ramos-Casals M, Robles A, Brito-Zerуn P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36(3): 189-196

17. Ahmed MS, Wong CF, Shawki H, et al. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol 2008; 69(4): 298-301

18. Ohta S, Yokoyama H, Wada T et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33(6): 1040-1048

19. Bruchfeld A, Lindahl K, Stеhle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18(8): 1573-1580

20. McHutchison JG, Manns MP, Brown RS Jr, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102(4): 880-889

21. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49(4): 1335-1374

22. Rossini A, Ravaggi A, Biasi L et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26(4): 1012-1017

23. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels.Hepatology 1997; 26[Suppl1]:133S-136S

24. Jamal MM, Soni A, Quinn PG et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States. Hepatology 1999; 30(5): 1307-1311

25. http: //consensus.nih.gov/2002/2002HepatitisC2002116html.htm